MedPath
FDA Approval

Orphenadrine Citrate

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Akorn
DUNS: 117693100
Effective Date
January 29, 2024
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Orphenadrine(30 mg in 1 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

W. R. Grace & Co.-Conn.

Akorn

788779192

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Orphenadrine Citrate

Product Details

NDC Product Code
17478-538
Application Number
ANDA040484
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
January 29, 2024
Code: X0A40N8I4SClass: ACTIBQuantity: 30 mg in 1 mL
Sodium MetabisulfiteInactive
Code: 4VON5FNS3CClass: IACTQuantity: 2.0 mg in 1 mL
WaterInactive
Code: 059QF0KO0RClass: IACT
Sodium ChlorideInactive
Code: 451W47IQ8XClass: IACTQuantity: 5.8 mg in 1 mL
Sodium HydroxideInactive
Code: 55X04QC32IClass: IACT
© Copyright 2025. All Rights Reserved by MedPath